With all eyes on Chinese-only oncology data, Coherus and Junshi uncork win for PD-1 drug in esophageal cancer

Kyle Blankenship

After the FDA’s recent shellacking of Eli Lilly and Innovent’s immune checkpoint drug sintilimab, all eyes are on the next drugmakers up for agency review …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With all eyes on Chinese-only oncology data, Coherus and Junshi uncork win for PD-1 drug in esophageal cancer

Kyle Blankenship

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Bristol Myers sues the federal government over 340B, following other drugmakers

With all eyes on Chi­nese-on­ly on­col­o­gy da­ta, Co­herus and Jun­shi un­cork win for PD-1 drug in esophageal can­cer

Kyle Blankenship

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

With all eyes on Chinese-only oncology data, Coherus and Junshi uncork win for PD-1 drug in esophageal cancer

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Bristol Myers sues the federal government over 340B, following other drugmakers